Steatosis and hepatitis C virus: Mechanisms and significance for hepatic and extrahepatic disease

Lonardo, Amedeo; Adinolfi, Luigi Elio; Loria, Paola; Carulli, Nicola; Ruggiero, Giuseppe; Day, Christopher P.

doi:10.1053/j.gastro.2003.11.020

Cited by 428 publications

(344 citation statements)

References 151 publications

Supporting

Mentioning

308

Contrasting

Unclassified

Order By: Relevance

“…Steatosis occurs more than twice as often as would be expected in the general population 4 and is found in approximately 50% of patients with CHC. Data suggest that both viral and host metabolic factors contribute to the genesis of hepatic steatosis in the setting of CHC (Figure 1).…”

Section: Pathogenesis Of Hepatic Steatosis and Steatohepatitis In Thementioning

confidence: 77%

Steatosis and Chronic Hepatitis C Infection: Mechanisms and Significance

Harrison

2005

Clinical Gastroenterology and Hepatology

View full text Add to dashboard Cite

Section: Pathogenesis Of Hepatic Steatosis and Steatohepatitis In Thementioning

confidence: 77%

Steatosis and Chronic Hepatitis C Infection: Mechanisms and Significance

Harrison

2005

Clinical Gastroenterology and Hepatology

View full text Add to dashboard Cite

“…Interest in these cytokines comes from the evidence that their expression in terms of blood levels is significantly modulated in patients which are either obese and/or affected by metabolic alterations resulting in insulin-resistance [49]. In particular, obesity and insulin resistance have been shown to correlate with fibrogenic progression in CLDs [49,50]; moreover, accumulation of white adipose tissue or type 2 diabetes, as features of the so-called metabolic syndrome (MS), are considered as significant risk factors for the progression of NASH to cirrhosis. Along these lines, a consistent bulk of recent literature data indicates that different member of the adipokine family, including at least leptin, adiponectin, resistin and a few emerging other adipokines, can be considered as effective modulators of liver fibrogenesis.…”

Section: Adipokinesmentioning

confidence: 99%

Cellular and molecular mechanisms in liver fibrogenesis

Novo

Cannito

Paternostro

et al. 2014

Archives of Biochemistry and Biophysics

179

194

View full text Add to dashboard Cite

“…Current estimations find that more than one-fourth of HIV-infected patients are coinfected with HCV, 1 and HCV-related deaths are now the third cause of death in HIVinfected patients. 2 When compared to the general population, HCVinfected patients have a 2.5-fold increased risk of developing hepatic steatosis (HS), 3 often associated with faster fibrosis progression and more severe hepatic fibrosis, 4 an increased risk of hepatocellular carcinoma development, 5 and lower rates of sustained viral response to HCV antiviral therapy, mainly in genotype 3. 6 There are two types of HS in HCV infection, a viral-related HS and a metabolic-related HS.…”

mentioning

confidence: 99%

Hepatic Steatosis in Patients Coinfected with Human Immunodeficiency Virus/Hepatitis C Virus: A Meta-Analysis of the Risk Factors

2010

View full text Add to dashboard Cite

Hepatic steatosis (HS) is frequent in patients with hepatitis C virus (HCV) infection, occurring in 40%-80%, associating with metabolic and virus-related factors, namely, genotype 3 and viral load. Human immunodeficiency virus (HIV) infection and antiretroviral treatment seem to be risk factors for HS. Several studies addressed this issue in coinfected patients, with discrepant results. A meta-analysis was performed on the HS risk factors in coinfected patients. Eligible studies were identified through structured keywords including coinfection, HCV, HIV, and steatosis in relevant databases including PubMed. Pooled odds ratios (ORs) and confidence limits (CIs) were obtained with the random-effects model and the DerSimonian-Laird method. Twelve studies, including 1,989 coinfected patients, were selected. Twenty percent were infected with HCV genotype 3. The overall prevalence of HS was 50.8% (23%-72%). Four studies also included 1,540 HCV monoinfected patients, not showing an increased risk for HS in coinfected patients (OR 1.61, 95% CI 0.84-3.10, P 5 0.151). In coinfected patients, HS was associated with higher body mass index (OR 1.13, 95% CI 1.07-1.19, P < 0.001), diabetes mellitus (OR 2.32, 95% CI 1.32-4.07, P 5 0.003), elevated alanine aminotransferase levels (OR 1.28, 95% CI 1.02-1.61, P 5 0.035), necroinflammatory activity (OR 1.72, 95% CI 1.11-2.67, P 5 0.016), and fibrosis (OR 1.67, 95% CI 1.20-2.34, P 5 0.003). No associations were found between HS and gender, other metabolic factors (dyslipidemia, glucose, metabolic syndrome), HCV-related factors (genotype, viral load), or HIV-related factors (viral load, CD4 count, antiretroviral therapy, and class of medication). Conclusion: In coinfected patients, HS does not seem to be more frequent than in HCV monoinfected patients and is mostly associated with metabolic factors, such as increased weight, diabetes mellitus, and more severe liver disease. The fact that no associations with HCV factors were found may be due to the small percentage of genotype 3-infected patients. (HEPATOLOGY 2010;52:71-78)

show abstract

Steatosis and hepatitis C virus: Mechanisms and significance for hepatic and extrahepatic disease

Cited by 428 publications

References 151 publications

Steatosis and Chronic Hepatitis C Infection: Mechanisms and Significance

Steatosis and Chronic Hepatitis C Infection: Mechanisms and Significance

Cellular and molecular mechanisms in liver fibrogenesis

Hepatic Steatosis in Patients Coinfected with Human Immunodeficiency Virus/Hepatitis C Virus: A Meta-Analysis of the Risk Factors

Contact Info

Product

Resources

About